At a glance
ClinicalIndex Comparison RecordN/ACompleted· 298 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Compare Effectiveness of Tofacitinib 11 mg QD to Tofacitinib 5 mg BID
In Brief
An observational study for Arthritis Rheumatoid. Completed, enrolled 298 participants across 1 site.
Detailed Summary
It is hypothesized that patients prescribed tofacitinib 11 mg Modified Release (MR) formulation once daily (QD) will achieve similar benefit to those prescribed tofacitinib 5 mg twice a day (BID) dosage in real world use. This study will therefore seek to compare the effectiveness of the MR 11 mg QD regimen to the IR 5 mg BID regimen for the treatment of RA in a real-world registry of RA patients.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis Rheumatoid
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartSep 2018
Primary CompletionAug 2019
First PostedFeb 2020
TodayJul 2026
First PostedFeb 12, 2020
Enrollment StartSep 30, 2018
Primary CompletionAug 31, 2019
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 6.4 years ago